Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.262
-0.023 (-8.04%)
At close: Apr 28, 2026, 4:00 PM EDT
0.270
+0.008 (3.01%)
Pre-market: Apr 29, 2026, 5:34 AM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$12,100
Profits / Employee
-$6,050,624
Market Cap
27.42M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Kyntra Bio | 34 |
| Senti Biosciences Holdings | 34 |
| Lisata Therapeutics | 21 |
| Tevogen Bio Holdings | 18 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Apollomics | 13 |
OTLK News
- 5 days ago - Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewsWire
- 6 days ago - Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 days ago - Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 21 days ago - Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - GlobeNewsWire
- 4 weeks ago - Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Outlook Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - GlobeNewsWire